Last reviewed · How we verify
Dexbenzetimide (DEXETIMIDE)
Dexbenzetimide (generic name: DEXETIMIDE) is a dexetimide drug. It is currently in Phase 2 development for Neuroleptic-induced Parkinsonism.
Dexbenzetimide works by blocking the M2 muscarinic acetylcholine receptor, which helps to regulate muscle contractions and other bodily functions.
Dexbenzetimide, also known as DEXETIMIDE, is a small molecule drug that targets the muscarinic acetylcholine receptor M2. It is classified as a dexetimide and is used to treat neuroleptic-induced Parkinsonism. The commercial status of Dexbenzetimide is currently unknown, and it is not clear if it is patented or available as a generic medication. Dexbenzetimide's safety considerations are also unclear due to a lack of available information. Further research is needed to fully understand its pharmacological properties and clinical applications.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | DEXETIMIDE |
|---|---|
| Drug class | dexetimide |
| Target | Muscarinic acetylcholine receptor M2 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's muscles are like a car's engine, and the M2 receptor is like the accelerator pedal. When the M2 receptor is blocked, it's like taking your foot off the pedal, which can help to reduce muscle contractions and alleviate symptoms of neuroleptic-induced Parkinsonism.
Approved indications
- Neuroleptic-induced Parkinsonism
Common side effects
Key clinical trials
- Dynamic Networks in Depression Treatment: Mechanisms of Change in Pharmacological, Psychological and Combined Treatment of Depression (PHASE4)
- TDM-Guided Treatment With SSRIs in Hospitalized Adults and Children (PHASE4)
- Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder (NA)
- Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease (PHASE2)
- Acupuncture and Escitalopram for Treating Major Depression Clinical Study (NA)
- Pattern Separation in Major Depressive Disorder (PHASE1)
- Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D) (PHASE4)
- Treatment of Psoriasis With Depression and/or Anxiety With Methotrexate vs Combined Methotrexate and Antidepressant (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexbenzetimide CI brief — competitive landscape report
- Dexbenzetimide updates RSS · CI watch RSS
Frequently asked questions about Dexbenzetimide
What is Dexbenzetimide?
How does Dexbenzetimide work?
What is Dexbenzetimide used for?
What is the generic name of Dexbenzetimide?
What drug class is Dexbenzetimide in?
What development phase is Dexbenzetimide in?
What does Dexbenzetimide target?
Related
- Drug class: All dexetimide drugs
- Target: All drugs targeting Muscarinic acetylcholine receptor M2
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Neuroleptic-induced Parkinsonism
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing